Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Instil Bio, Inc.NASDAQ: TIL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$12K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$24K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$12K or moves back toward the trailing-twelve-month quarterly average of -$6K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12K— QoQ
Last fiscal yearDec 2025
-$534K— YoY
LTMMar 2026
-$24K+96.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(534K) USD
Year-over-year change
—

Gross Profit vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +96.8% is the 2nd highest of 9, against a peer median of -24.1%.
TIL Competitors
Gross Profit for TIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
SRZNSurrozen, Inc.LTM Mar 2026$7.43M USD-34.0%-31.7%99.1%
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K USD+100.0%——
TILInstil Bio, Inc.LTM Mar 2026-$24K USD+96.8%——
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$119.31K CAD+26.6%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K USD-100.6%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$711K USD-14.3%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
Peer median (excluding TIL) —-24.1%-20.5%90.6%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue05.99M00534K
Gross Profit0(5.99M)00(534K)
Gross Margin—————
Research & Development107.25M141.06M39.6M11.84M10M
Selling, General & Admin51.31M62.24M47.55M44.21M27.22M
Operating Expenses155.56M200.18M159.17M73.54M52.37M
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
EBITDA(152.51M)(217.38M)(147.12M)(62.53M)(65.01M)
EBITDA Margin—————
Operating Income(155.56M)(206.17M)(159.17M)(73.54M)(52.91M)
Operating Margin—————
Interest Income80K3.66M8.87M6.99M3.86M
Interest Expense01.88M5.21M8.99M5.83M
Other Income / Expenses(1.2M)(19.08M)3.08M(594K)(18.47M)
Income Before Tax(156.76M)(225.25M)(156.09M)(74.14M)(71.37M)
Pre-Tax Margin—————
Income Tax Expense39K(2.07M)000
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Net Margin—————
EPS (Basic)(29.60)(34.46)(24.00)(11.39)(10.70)
EPS (Diluted)(29.60)(34.46)(24.00)(11.39)(10.70)
Weighted Avg Shares5.3M6.48M6.5M6.51M6.67M
Weighted Avg Shares (Diluted)5.3M6.48M6.5M6.51M6.67M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.